Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia

dc.contributor.authorPadrones, Susana
dc.contributor.authorGarcia Vidal, Carolina
dc.contributor.authorFernández-Serrano, Silvia
dc.contributor.authorFernández Cervilla, Ana Belén
dc.contributor.authorMasuet Aumatell, Cristina
dc.contributor.authorCarratalà, Jordi
dc.contributor.authorCorominas Sánchez, Mercè
dc.contributor.authorArdanuy Tisaire, María Carmen
dc.contributor.authorGudiol i Munté, Francesc
dc.contributor.authorManresa, Federico
dc.contributor.authorDorca i Sargatal, Jordi
dc.date.accessioned2018-11-20T09:20:30Z
dc.date.available2018-11-20T09:20:30Z
dc.date.issued2010-10
dc.date.updated2018-11-20T09:20:31Z
dc.description.abstractThe aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococal pneumonia treated either with β-lactam monotherapy or with combination therapy (β-lactam plus fluoroquinolone). Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10, and TNF-α were determined on days 0, 1, 2, 3, 5, and 7. Patients on β-lactam monotherapy were compared with those receiving combination therapy. Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with β-lactam monotherapy and those treated with combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 h (p = 0.016). Our data suggest that systemic expression of IL-6 production in patients with PP correlates with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 h.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec580668
dc.identifier.issn0934-9723
dc.identifier.pmid20567869
dc.identifier.urihttps://hdl.handle.net/2445/126250
dc.language.isoeng
dc.publisherSpringer Verlag
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1007/s10096-010-0993-0
dc.relation.ispartofEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010, vol. 29, num. 10, p. 1243-1251
dc.relation.urihttps://doi.org/10.1007/s10096-010-0993-0
dc.rights(c) Springer Verlag, 2010
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationPneumococs
dc.subject.classificationAntibiòtics
dc.subject.classificationCitoquines
dc.subject.otherStreptococcus pneumonia
dc.subject.otherAntibiotics
dc.subject.otherCytokines
dc.titleImpact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
580668.pdf
Mida:
379.51 KB
Format:
Adobe Portable Document Format